Cargando…

Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease

The aim of the present study was to examine cerebral vasoconstriction in patients with chronic high altitude disease [cerebrovascular reactivity (CVR)], and to evaluate differences in alterations of brain vascular contractile reactivity of chronic mountain sickness (CMS) patients and healthy control...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shizheng, Hao, Guisheng, Zhang, Shukun, Jiang, Dongmei, Wuren, Tana, Luo, Junming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991730/
https://www.ncbi.nlm.nih.gov/pubmed/27485004
http://dx.doi.org/10.3892/mmr.2016.5555
_version_ 1782448899873570816
author Wu, Shizheng
Hao, Guisheng
Zhang, Shukun
Jiang, Dongmei
Wuren, Tana
Luo, Junming
author_facet Wu, Shizheng
Hao, Guisheng
Zhang, Shukun
Jiang, Dongmei
Wuren, Tana
Luo, Junming
author_sort Wu, Shizheng
collection PubMed
description The aim of the present study was to examine cerebral vasoconstriction in patients with chronic high altitude disease [cerebrovascular reactivity (CVR)], and to evaluate differences in alterations of brain vascular contractile reactivity of chronic mountain sickness (CMS) patients and healthy controls. Alterations of endothelin (ET) and its receptor, as well as endothelial nitric oxide synthase (eNOS) levels in the plasma were examined to determine the cerebral reservation capacities in CMS patients. Transcranial Doppler ultrasound and carbon dioxide analysis methods were used to detect the CVR variances. At the same time, enzyme-linked immunosorbent assay approaches were utilized to detect the ET and ET B receptor and the eNOS levels in serum of the CMS patients and healthy controls. CVR and CVRI levels in CMS patients were lower than those of the healthy control subjects and the difference was statistically significant (P<0.05). By contrast, eNOS and ET-1 levels were not statistically significant for CMS and healthy controls (P>0.05). However, the ET receptor concentration level was higher in CMS than the healthy controls. Thus, ET-1 may not be a direct etiological variation but may play compensatory roles in CMS patients. The results of the study may provide scientific clues for the prevention and treatment of CMS with higher blood coagulation states of cerebral infarction in patients with chronic high altitude disease.
format Online
Article
Text
id pubmed-4991730
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-49917302016-08-26 Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease Wu, Shizheng Hao, Guisheng Zhang, Shukun Jiang, Dongmei Wuren, Tana Luo, Junming Mol Med Rep Articles The aim of the present study was to examine cerebral vasoconstriction in patients with chronic high altitude disease [cerebrovascular reactivity (CVR)], and to evaluate differences in alterations of brain vascular contractile reactivity of chronic mountain sickness (CMS) patients and healthy controls. Alterations of endothelin (ET) and its receptor, as well as endothelial nitric oxide synthase (eNOS) levels in the plasma were examined to determine the cerebral reservation capacities in CMS patients. Transcranial Doppler ultrasound and carbon dioxide analysis methods were used to detect the CVR variances. At the same time, enzyme-linked immunosorbent assay approaches were utilized to detect the ET and ET B receptor and the eNOS levels in serum of the CMS patients and healthy controls. CVR and CVRI levels in CMS patients were lower than those of the healthy control subjects and the difference was statistically significant (P<0.05). By contrast, eNOS and ET-1 levels were not statistically significant for CMS and healthy controls (P>0.05). However, the ET receptor concentration level was higher in CMS than the healthy controls. Thus, ET-1 may not be a direct etiological variation but may play compensatory roles in CMS patients. The results of the study may provide scientific clues for the prevention and treatment of CMS with higher blood coagulation states of cerebral infarction in patients with chronic high altitude disease. D.A. Spandidos 2016-09 2016-07-27 /pmc/articles/PMC4991730/ /pubmed/27485004 http://dx.doi.org/10.3892/mmr.2016.5555 Text en Copyright: © Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wu, Shizheng
Hao, Guisheng
Zhang, Shukun
Jiang, Dongmei
Wuren, Tana
Luo, Junming
Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease
title Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease
title_full Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease
title_fullStr Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease
title_full_unstemmed Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease
title_short Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease
title_sort cerebral vasoconstriction reactions and plasma levels of etbr, et-1, and enos in patients with chronic high altitude disease
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991730/
https://www.ncbi.nlm.nih.gov/pubmed/27485004
http://dx.doi.org/10.3892/mmr.2016.5555
work_keys_str_mv AT wushizheng cerebralvasoconstrictionreactionsandplasmalevelsofetbret1andenosinpatientswithchronichighaltitudedisease
AT haoguisheng cerebralvasoconstrictionreactionsandplasmalevelsofetbret1andenosinpatientswithchronichighaltitudedisease
AT zhangshukun cerebralvasoconstrictionreactionsandplasmalevelsofetbret1andenosinpatientswithchronichighaltitudedisease
AT jiangdongmei cerebralvasoconstrictionreactionsandplasmalevelsofetbret1andenosinpatientswithchronichighaltitudedisease
AT wurentana cerebralvasoconstrictionreactionsandplasmalevelsofetbret1andenosinpatientswithchronichighaltitudedisease
AT luojunming cerebralvasoconstrictionreactionsandplasmalevelsofetbret1andenosinpatientswithchronichighaltitudedisease